-
-
-
-
-
-
-
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
-
-
-
-
-
-
-
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
-
-
-
-
-
-
-
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
-
-
-
-
-
-
-
CENTOGENE Extends Partnership With Takeda
-
-
-
-
-
-
-
Takeda Accelerates Transformation: Solid FY2019 Results, Confidence in FY2020 Growth Momentum
-
-
-
-
-
-
-
Takeda (TAK) Announces NEJM Published Results of Phase 2 Trial Evaluating its TAK-620 as Potential Treatment of CMV Infection
-
1,203,207 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

